PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.35%
Positive revenue growth while 6617.T is negative. John Neff might see a notable competitive edge here.
-3.36%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-38.35%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-18.20%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-55.37%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-55.32%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-55.32%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.00%
Share reduction while 6617.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-93.11%
Negative 10Y revenue/share CAGR while 6617.T stands at 9.39%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-26.07%
Negative 5Y CAGR while 6617.T stands at 9.39%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-7.29%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.77%
Net income/share CAGR above 1.5x 6617.T's 55.07% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
-2690.48%
Negative 5Y net income/share CAGR while 6617.T is 55.07%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-152.21%
Negative 3Y CAGR while 6617.T is 32.25%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
52.20%
5Y equity/share CAGR above 1.5x 6617.T's 2.88%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
35.88%
3Y equity/share CAGR above 1.5x 6617.T's 4.78%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.62%
Firm’s AR is declining while 6617.T shows 1.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
12.04%
Inventory growth well above 6617.T's 8.44%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.21%
Positive asset growth while 6617.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-3.64%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
9.70%
We have some new debt while 6617.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-100.00%
Our R&D shrinks while 6617.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
2.92%
SG&A declining or stable vs. 6617.T's 10.75%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.